Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash & Current Investments (2020 - 2026)

Design Therapeutics' Cash & Current Investments history spans 2 years, with the latest figure at $384.1 million for Q4 2021.

  • On a quarterly basis, Cash & Current Investments rose 15731.16% to $384.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $384.1 million, a 15731.16% increase, with the full-year FY2021 number at $384.1 million, up 15731.16% from a year prior.
  • Cash & Current Investments hit $384.1 million in Q4 2021 for Design Therapeutics, up from $357.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for DSGN hit a ceiling of $402.8 million in Q2 2021 and a floor of $2.4 million in Q4 2020.